Drug intelligence / Profile preview

Pigoline

Development stage: Preclinical
Lead developer: EuroEspes
Modality: Small Molecules

Overview

Pigoline is a preclinical-stage compound developed by EuroEspes for the potential treatment of cerebral vascular occlusion and neurodegeneration. Preclinical research conducted between 2012 and 2014 evaluated the in vivo and in vitro effects of Pigoline in animal models of cerebral vascular occlusion and neurodegenerative diseases. However, its exact chemical structure, molecular target, and current development status remain undisclosed.

Beyond the preview

Go deeper on Pigoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pigoline.

Explore the full profile